Please ensure Javascript is enabled for purposes of website accessibility

Medtronic Reports Significant COVID-19 Impact on Its Business

By Prosper Junior Bakiny - Apr 24, 2020 at 2:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pandemic has sharply reduced the number of medical procedures being performed that use the company's medical devices.

Medtronic's (MDT -0.25%) business is taking a serious hit as a result of the COVID-19 pandemic. With overwhelmed healthcare systems around the world diverting resources and personnel to coronavirus patients, the number of surgical procedures being performed with Medtronic's devices has declined sharply. As a result, the company has experienced deep revenue decreases over the past few weeks across every region in which it operates. In Western Europe, where Medtronic typically generates about 20% of its top line, the company started experiencing year-over-year revenue declines of 20% to 30% the week of March 23. 

In the U.S., where Medtronic makes a little over half of its revenue, the company said its top line started decreasing by about 60% year over year the week of March 16. What's more, management is expecting the drag on the bottom line to be even worse. The company has continued to operate its medical device manufacturing at (or near) full capacity despite the decrease in sales. In short, investors should expect Medtronic's financial results for its current quarter -- Q4 of its fiscal 2020 -- to be ugly.

Robot-assisted surgical device

Image Source: Getty Images.

Despite these challenges, Medtronic is confident that it can handle the current crisis and come out of it in one piece. The healthcare company has a strong balance sheet, "with approximately $11 billion in cash and investments as of the most recent quarter, and an undrawn $3.5 billion credit facility." Management also pointed out  that Medtronic has no public debt maturing until March 2021.

Medtronic shares today are trading at about 19% below their February peak. But  given the company's solid financial position, perhaps that makes this an opportunity for investors to buy in at a discount. After all, its leading position in the medical devices industry should allow Medtronic to get back to its usual strong performance after the pandemic recedes

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Medtronic plc Stock Quote
Medtronic plc
MDT
$95.00 (-0.25%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.